{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-150894","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.212511+00:00","generated_at":"2026-06-25T14:48:04.520981+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galera Q1 net loss $15.4M; plans avasopasem NDA by end 2022","bullets":["Net loss $(15.4M) ($0.58/share) vs $(18.7M) ($0.75) in Q1 2021; cash $60.9M funds into H2 2023.","Plans to submit NDA for avasopasem for severe oral mucositis by end of 2022 after FDA discussions.","Phase 3 ROMAN data accepted for oral presentation at 2022 ASCO; positive Phase 2a AESOP data reported.","R&D expenses $8.1M (down from $12.4M); G&A expenses $5.0M (flat).","Enrollment ongoing in Phase 2b GRECO-2 trial of rucosopasem for pancreatic cancer and Phase 1/2 GRECO-1 for NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-150894","json":"https://secwatch.observer/filing/0001193125-22-150894.json","markdown":"https://secwatch.observer/filing/0001193125-22-150894.md","text":"https://secwatch.observer/filing/0001193125-22-150894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522150894/0001193125-22-150894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522150894/d277547d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T14:48:04.520981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}